Kornimate/medical-research-clean huggingface dataset:
mental health impact of the covid-19 pandemic among migrants in chile

Conditions: Anxiety; Depression; Stress, Psychological; Loneliness; Social Isolation

Summary: the mental health of a representative sample of immigrants residing in santiago, chile (string cohort) was assessed nine months prior to the covid-19 pandemic (t0). evidence suggests that social isolation affects mental health by increasing symptoms of anxiety and depression. one of the main components of the current covid-19 pandemic is the social isolation imposed on the population. this study seeks to explore the short (t1) and long-term (t2) effects of the pandemic on the psychological wellbeing of the cohort. specific aims are to 1. describe the variations in the levels of mental health problems (i.e. symptoms of depression, anxiety, post-traumatic stress, sleep difficulties) and wellbeing of immigrants during the first (t1) and second follow-up (t2) 2. calculate the short (t1) and long-term (t2) effects of social isolation on the levels of mental health problems of the immigrant population, and 3. identify risk / protective factors associated with a short (t1) and long-term (t2) increase in mental health problems

participants were interviewed at baseline (t0) 8 months before the covid-19 pandemic. an online survey will be applied in two follow-up moments during the pandemic: 1. at 9 months (also 1 month after lockdown measures imposed) (t1) 2. at 18 months (also 10 months after lockdown measures imposed) (t2)

Eligibility criteria:
inclusion criteria: * country of birth other than chile * time since arrival to chile: 3 months (at baseline) exclusion criteria: * unable to understand spanish

Keywords: migrants depression anxiety covid-19 within-group longitudinal design
myocene sensivity to cycling intensities

Conditions: Fatigue Intensity

Summary: this study aims to address this gap by assessing lff following different efforts in cycling, aiming to identify a pattern. also, we expect that this study helps to clarify to which efforts (prolonged vs short) are more likely to trigger substantial changes in lff responses.


Eligibility criteria:
inclusion criteria: * road cyclists exclusion criteria: * injured or recently injured participants
icanwork: a randomized controlled trial

Conditions: Cancer-related Problem/Condition; Survivorship; Quality of Life

Summary: the aim of this study is to evaluate the effectiveness of the icanwork intervention in assisting cancer survivors (cs) to return to work (rtw) and its impact on their health-related quality of life (qol), health service utilization, rtw readiness, time to rtw, and work capacity.

the icanwork intervention comprises several elements related to health and work, taken from the latest reviews that recommend a remote and individual intervention, led by a vocational rehabilitation counsellor (vrc), experts in assisting rtw for cs. the intervention includes 6 sessions with a vrc and 1-4 sessions with an occupational therapist (ot). a total of 270 cs will be recruited into 2 groups (intervention or control). the duration of this study is 24 months. study participants will complete electronic questionnaires measuring study variables at baseline before randomization and at 6-month, 12-month, 18-month, and 24-month follow-ups.

Eligibility criteria:
inclusion criteria: * diagnosed with cancer (all types) treated with curative intent and of working age (between 18 and 65 at the time of diagnosis) * gainfully employed at the time of diagnosis (full or part-time, including students) * still on sick leave, including long-term disability leave, but for less than 2 years * has not started to return to work, since stopping due to cancer * can read and understand english or french * reside in canada. exclusion criteria: - if the cancer survivor's physicians consider returning to work unwise, such as due to a metastatic cancer diagnosis

Keywords: return to work cancer survivors vocational rehabilitation randomized controlled trial
metabolism of patients with genetically caused cardiac arrhythmia

Conditions: Long QT Syndrome

Summary: loss-of-function mutations in voltage-gated potassium channels cause long qt syndrome (lqts) due to a prolonged cardiac repolarisation phase. hypoteses: patients with loss-of-function mutations also exhibit altered hormone release upon glucose ingestion.

loss-of-function mutations in voltage-gated potassium channels cause long qt syndrome (lqts) due to a prolonged cardiac repolarisation phase. voltage-gated potassium (kv-) channels are known for their relation to malignant cardiac arrhythmias, but also play a role in pancreatic alpha- and beta cell hormone secretion, and possibly in incretin hormone secretion. we hypothesised that patients with loss-of-function mutations also exhibit altered hormone release upon glucose ingestion.

Eligibility criteria:
inclusion criteria: lqts gain of function matched healthy controls exclusion criteria: none
corticoids in severe community-acquired pneumonia (cap)

Conditions: Community-Acquired Pneumonia

Summary: the purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (cap) (fine v). the hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe cap without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.

community acquired pneumonia (cap) is associated with a local and systemic inflammatory response conducted by different pro and counter inflammatory cytokines. the evolution of the infection is mainly dependent on the intensity of the inflammatory response. the aim of the project is to determine the clinical usefulness of methylprednisolone treatment (0,5 mg/ kg weight every 12h for 5 days in patients with severe cap and an excessive inflammatory response( patients identified based on a cut-off point of the reactive c protein (rcp) of 15 mg/dl). a randomized double blind placebo controlled study with two arms will be performed: the study group (patients with excessive inflammatory response) will receive methylprednisolone + antibiotics. control group will receive placebo + antibiotics. patients older than 18 years with fine v pneumonia will be recruited. clinical data and prognostic factors (apache ii and, sofa scores, etiology, mortality at icu and at 28 days) will be collected.

Eligibility criteria:
inclusion criteria: * severe community-acquired pneumonia fine v * crp \>=15 mg/100 ml exclusion criteria: * major contraindications for corticosteroids, such as uncontrolled diabetes, immunosuppression * previous glucocorticoid treatment during the previous month * documented extrapulmonary infection * previous hospitalization in the previous month

Keywords: severe cap adjuvant therapy glucocorticoids cap fine v with c-reactive protein >= 15 mg/100 ml
translation and validation of the "children and adolescent trauma screen" in french

Conditions: Child Psychiatry; Adolescent Psychiatry

Summary: child psychotraumatism and complex psychotraumatism, mainly consecutive to child maltreatment, is a major unaddressed public health issue. the investigators aim to translate and validate a screening scale to help professionals to better detect and refer children at risk of psychotraumatism. this study aims to validate the psychometric properties of a french version of the cats 2.0, in partnership with the original authors of the scale.


Eligibility criteria:
inclusion criteria: * child aged between 7 and 17 * at least an adult of reference (parent or tutor) reachable * agreement of adult of reference * for clinical population : have been potentially exposed to a potential traumatic event (according to dsm-v) exclusion criteria: * non-mastery of french language

Keywords: psychotraumatism children adolescent scale french translation validation
bifeprunox in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * understand nature of study * able to be managed in out-patient setting for long-term bifeprunox treatment exclusion criteria: * current primary diagnosis other than schizophrenia * suicide risk * diagnosis or history of substance abuse * uncontrolled hypertension

Keywords: double-blind study in the treatment of schizophrenia
circulating tumor cell analysis in patients with localized prostate cancer undergoing prostatectomy

Conditions: Prostate Cancer

Summary: this study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. the investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. these are called circulating tumor cells (ctcs). some early studies indicate the amount and type of ctcs in the blood can help determine the status of the tumor itself and the way it is responding to treatment. in this study, the investigators will compare the number of ctcs in the blood at different time frames before and after surgery to remove the prostate.

the investigators will collect a blood sample for the study when the participant has other blood tests drawn for their cancer treatment. the investigators will take one sample to check prostate specific antigen (psa) levels and another blood sample for ctc analysis. the investigators will be drawing blood at the following time points: screening; one day after surgery; 7-14 days after surgery; 3-6 months after surgery; at psa recurrence or at two years.

Eligibility criteria:
inclusion criteria: * male * 18 years of age or older * pathologically confirmed diagnosis of prostate adenocarcinoma * non-metastatic prostate cancer * planned radical prostatectomy at massachusetts general hospital exclusion criteria: * patients must not have received prior radiation therapy, hormone therapy, or other medical therapy for prostate cancer prior to prostatectomy. post-prostatectomy therapy at the discretion of the patient's treating physician(s) is allowed. * patients must not have metastatic prostate cancer * no prior or current diagnosis of epithelial malignancy, except for skin cancer (squamous cell carcinoma or basal cell carcinoma)

Keywords: circulating tumor cells ctc-chip
mucoadhesive film with/without acmella oleracea & triamcinolone acetonide for aphthous ulcers

Conditions: Aphthous Stomatitis

Summary: the purpose of this study is to evaluate the effectiveness of mucoadhesive film with or without acmella oleracea extract compared to standard treatment by using 0.1% triamcinolone acetonide in pain relief, promoting wound healing, healing time and satisfaction in 3 aspects included taste, product used and quality of life after using the product.

participants who consent and meet the inclusion criteria will be allocated into 3 groups using block randomization: group 1: mucoadhesive film with acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without acmella oleracea extract.

Eligibility criteria:
inclusion criteria: 1. healthy participants aged 18-50 years without any underlying diseases. 2. participants are voluntary and have signed the informed consent. 3. participants are literate. 4. participants can follow the treatment guidelines and follow up. 5. participants have one untreated oral ulcer lesion. * an ulcer has occurred within 48 hours. * the ulcer size is less than 10 mm. * the ulcer is clearly visible and located on non-keratinized oral mucosa such as buccal mucosa, labial mucosa, alveolar mucosa, or buccal vestibule. * the ulcer must be painful. 6. if an ulcer is caused by a denture or orthodontic appliance, the cause must be eliminated before participation. 7. participants must not be currently participating in any other clinical studies about oral ulcer exclusion criteria: 1. participants with allergies to herbal extracts, acmella oleracea, or steroids. 2. participants with chronic underlying diseases. 3. participants with underlying diseases that may affect wound healing. 4. participants receiving anti-analgesic drug, systemic steroids, antibiotics, hormones, nsaids, or any drugs that affect the oral mucosa. 5. oral ulcer lesion larger than 10 mm or lesions resembling herpetic form of aphthous ulcers. 6. oral ulcers are caused by infection or associated with systemic diseases. 7. participants with poor oral hygiene requiring emergency treatment. 8. participants who smoke or consume alcohol regularly. 9. participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

Keywords: oral ulcer
eus-guided procore-biopsy in diagnosing autoimmune pancreatitis

Conditions: Autoimmune Pancreatitis

Summary: the goal of this prospective study is to evaluate the feasibility of the core biopsy needle with reverse bevel (procore tm) in diagnosing autoimmune pancretitis


Eligibility criteria:
inclusion criteria: * patient age 18 years and older * patients with suspicion of autoimmune pancreatitis (based on the findings in eus and mri) exclusion criteria: * unable to obtain informed consent * asa class 4 and 5 * known pregnancy * contraindication for endoscopy or for biopsy sampling * patients with high suspicion on pancreatic cancer (based on the findings in radiology and eus)
international extranodal nk/t-cell lymphoma project

Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type

Summary: this study is to explore risk factors for poor progression-free survival (pfs) and overall survival (os) in enktl, and establish a prognostic model for enktl patients treated with non-anthracycline based treatment.

this is a retrospective cohort study using anonymized information from patients with enktl. the following criteria are required: (1) patients diagnosed with enktl, nasal type between january 1, 1995 and december 31, 2014; (2) patients treated with non-anthracycline based therapy as an initial treatment. the pathology of initial diagnosis was reviewed by designated pathologists.

Eligibility criteria:
inclusion criteria: * patients diagnosed with enktl, nasal type * patients diagnosed between january 1, 1995 and december 31, 2014 * patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis * nonanthracycline-based therapy includes the following treatments: * radiotherapy including concurrent chemoradiation * chemotherapy not including anthracycline such as doxorubicin (e.g. smile, vipd) the type of salvage treatment will not be a criterion for exclusion. thus, patients who had received various kinds of salvage treatment including anthracycline-containing regimens can be included. patients who had undergone autologous or allogeneic stem cell transplantation can also be included in the analysis if they satisfy the above-mentioned inclusion criteria. exclusion criteria: * patients who had received anthracycline-based therapy, such as chop or chop-like regimens, as the initial treatment. * patients who do not have pathology slides available for central review.
evaluating a fasting-mimicking diet in combination with immunotherapy in patients with non-small cell lung cancer

Conditions: Stage IV NSCLC; NSCLC; Immunotherapy; Fasting Mimicking Diet

Summary: the purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

cancer cells use an increased supply of glucose to make energy and do not have protection against fasting that normal cells do. because of this, researchers would like to study how fasting may help immunotherapy target cancer cells. initial studies suggest that fasting may decrease the side effects of immunotherapy and increase the chances of your cancer responding to the immunotherapy. patient populations will have non-small cell lung cancer in which pembrolizumab have been recommended to treat the cancer as part of standard care

Eligibility criteria:
inclusion criteria: * 18 years at the time of informed consent * ability to provide written informed consent and hipaa authorization. * eastern cooperative group (ecog) performance status of 0 to 2 * newly diagnosed histologically or cytologically confirmed stage iv non-small cell lung cancer (nsclc). patients with locally advanced nsclc that are not candidates for definitive therapy but are candidates for trial are allowed per investigator discretion. * bmi 19 kg/m2 * patients should be enrolled prior to starting standard of care immunotherapy for the treatment of stage iv nsclc. patients should be on pd (l)1 inhibitor alone (i.e., with pd-l1 expression 50%) in the metastatic setting. the investigators will allow single agent pembrolizumab only as the checkpoint inhibitor. * patients requiring palliative radiation or definitive radiation to an oligometastatic disease prior to the initiation of single agent checkpoint inhibitors are allowed once radiation has been completed and patients have recovered from toxicities. exclusion criteria: * self-reported weight loss of \> 10% in the 6 weeks prior to study entry * history of symptomatic hypoglycemia or uncontrolled diabetes * prior therapies with inhibitors of insulin growth factor i(igf-1) such as linsitinib or picropodophyllin * concurrent use of somatostatin * concurrent use of immunosuppressive medications including sirolimus, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, dexamethasone, or cyclosporine * significant food allergies which would make the subject unable to consume the food provided. * history or current evidence of any uncontrolled medical or psychiatric condition, therapy that may confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the participating subject as deemed by the treating investigator. * pregnant or lactating females are not eligible.

Keywords: pd1 inhibitors phase 2 open label nsclc fasting
survey of cabozantinib used to treat people with renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: this study is a survey in japan of cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. the study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. the main aim of the study is to check for side effects from cabozantinib. during the study, participants with renal cell carcinoma will take cabozantinib tablets according to their clinic's standard practice. the study doctors will check for side effects from cabozantinib for 26 weeks.

the drug being tested in this study is called cabozantinib tablets. this tablet is being tested to treat people who have radically unresectable or metastatic renal cell carcinoma. this study is an observational (non-interventional) study and will look at occurrence of adverse drug reactions (or adverse events) of cabozantinib tablets in the routine clinical setting. the planned number of observed patients will be approximately 300. this multi-center observational trial will be conducted in japan.

Eligibility criteria:
inclusion criteria: patients with radically unresectable or metastatic renal cell carcinoma who do not meet the following exclusion criterion are eligible. exclusion criteria: a patient who has a history of hypersensitivity to any component of cabozantinib.
regimen switch after intensive insulin therapy

Conditions: Insulin

Summary: insulin intensive therapy have traditionally been considered a sequential therapy in type 2 diabetes last choice, a number of guidelines and consensus recommendations insulin intensive therapy can be as obvious hyperglycemia in patients with newly diagnosed t2dm part of a line, a subset of patients after insulin intensive treatment target often need to change to other treatments, especially for senile diabetes patients, due to its self management ability, simplify the insulin solution is more urgent. current clinical guidelines do not provide specific clinical guidance, such as the timing and method of switch after initial insulin intensive therapy. the purpose of this study was to explore the timing, suitable population and conversion methods of insulin regimens after treatment.

selecting initial insulin intensive therapy during the period of hospitalization in patients with type 2 diabetes, collect the basic information and biochemical information collection, including gender, age, duration of diabetes, intensive glucose-lowering treatment plan before treatment, diabetes complications, merger disease, smoking, drinking, height, weight, blood pressure, fasting glucose, glycosylated hemoglobin and glycosylated serum protein, insulin, c-peptide, liver and kidney function, blood lipid, blood routine, hypoglycemia is happening almost 1 month. follow-up was conducted in january, march and june. endocrinologists decide whether to continue the original hypoglycemic regimen or adjust it according to the glycemic control goals, islet β-cell function, diabetes complications, complications, hypoglycemia and other combination drugs, as well as patients' treatment willingness and compliance. to compare the timing of conversion of treatment regimens, the proportion of conversion to each regimen and the situation of reaching the standard, and to further analyze and compare the characteristics of people who switched to different regimens, in order to establish the basis for the selection of adjustment regimens after insulin treatment.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes; * patients who started intensive insulin therapy during hospitalization * age ≥18 years old exclusion criteria: * type 1 diabetes, special type diabetes * acute complications of diabetes (diabetic ketoacidosis, hyperglycemia and hyperosmolarity) * severe infection * pregnancy or planned pregnancy * participating in other clinical studies or trials